Drug Profile
Amphetamine sulfate oral - Arbor Pharmaceuticals
Alternative Names: AR-19; EVEKEO ODTLatest Information Update: 27 Jun 2022
Price :
$50
*
At a glance
- Originator Arbor Pharmaceuticals
- Class Amphetamines; Antipsychotics; Behavioural disorder therapies; Neuropsychotherapeutics; Small molecules
- Mechanism of Action Adrenergic receptor agonists; Central nervous system stimulants; Diagnostic imaging enhancers; Trace amine-associated receptor 1 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Attention-deficit hyperactivity disorder
Most Recent Events
- 27 Jun 2022 Discontinued - Preregistration for Attention-deficit hyperactivity disorder (In adolescents, In children, In the elderly, In adults) in USA (PO) (Azurity Pharmaceuticals pipeline, June 2022)
- 11 Sep 2020 Efficacy and safety data from a phase III trial in Attention-deficit hyperactivity disorder released by Arbor Pharmaceuticals
- 13 May 2020 FDA assigns PDUFA action date of 15/11/2020 for amphetamine sulphate for Attention-deficit hyperactivity disorder (In adolescents, In children, In adults, In the elderly) (PO, Capsule)